ADMA Biologics Financials - Benzinga

ADMA Biologics Inc

ADMANASDAQ

Trade with Public

Trade with Public

$9.38

-0.14-1.47%

近くで: Sep 25, 5:00 PM EST

$9.44

0.060.64%

時間外: Sep 25, 4:16 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

ADMA Biologics Financials

ADMA Biologics (ADMA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est

ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.

Benzinga Newsdesk

PRO
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from

Benzinga Newsdesk

PRO
ADMA Biologics Withdraws Long-Term Guidance To Reflect Evolving U.S. Plasma Products And IG Market Competitive Dynamics

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est

ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.

Benzinga Newsdesk

PRO
ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14 per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved